4//SEC Filing
Nolet Chris 4
Accession 0001479290-22-000063
CIK 0001479290other
Filed
May 5, 8:00 PM ET
Accepted
May 6, 6:19 PM ET
Size
7.3 KB
Accession
0001479290-22-000063
Insider Transaction Report
Form 4
Nolet Chris
Director
Transactions
- Award
Stock Option (Right to buy)
2022-05-04+11,343→ 11,343 totalExercise: $18.12Exp: 2032-05-03→ Common Stock (11,343 underlying) - Award
Common Stock
2022-05-04+6,059→ 25,072 total
Footnotes (2)
- [F1]Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 4, 2023, subject to Mr. Nolet's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date.
- [F2]The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Mr. Nolet's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy.
Documents
Issuer
Revance Therapeutics, Inc.
CIK 0001479290
Entity typeother
Related Parties
1- filerCIK 0001782814
Filing Metadata
- Form type
- 4
- Filed
- May 5, 8:00 PM ET
- Accepted
- May 6, 6:19 PM ET
- Size
- 7.3 KB